Last reviewed · How we verify
protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series patent landscape — cliff calendar, originator estates, attackable patents
- protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series treatment landscape brief
- protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series treatment updates RSS
Related
- Treatment landscape: protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series patent cliff · protection against diphtheria tetanus pertussis whole cell hepatitis b poliomyelitis inactivated and haemophilus influenzae type b hib disease in infants and children from 6 weeks through 6 years of age when used in a 3 dose series CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing